4070 Stock Chart & Stats
€6.00
--
Market closed
€6.00
--
Day’s Range― - ―
52-Week Range€5.70 - €6.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€641.07M
Enterprise Value€167.54
Total Cash (Recent Filing)€202.79M
Total Debt (Recent Filing)€1.04M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 11, 2026EPS Estimate
-2.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-147.90
Shares Outstanding25,778,753
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€48.01Price Target Upside700.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-101.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Reduces Financial RiskFaeth's low debt relative to assets limits fixed financing obligations, reducing bankruptcy and interest-rate exposure. For an R&D-heavy biotech, limited leverage preserves strategic optionality and reduces near-term cash required for servicing debt, aiding longer-term program continuity.
Performance-based Equity Aligns Management And ShareholdersGranting options that vest only on a high sustained stock-price hurdle or equivalent change-of-control ties executive rewards to substantial value creation. This alignment incentivizes management to pursue durable, value-accretive milestones and disciplined capital allocation over opportunistic short-term moves.
Simplified Capital Structure And ATM Provide Financing FlexibilityConverting preferred into common simplifies the cap table and expands the common float, potentially improving liquidity. The established $150M at-the-market program gives structural access to capital as needed, supporting continued trial funding and operational continuity without relying solely on sporadic large financings.
Bears Say
No Meaningful Revenue BaseFaeth remains pre-revenue, meaning all value hinges on successful clinical development and commercialization. This prolongs dependence on external capital, increases binary risk tied to trial outcomes, and makes long-term sustainability contingent on execution rather than recurring business cash flows.
Sustained Negative Operating Cash FlowPersistent negative operating and free cash flow indicate ongoing consumption of capital to fund R&D and operations. Over months, this elevates dilution risk, forces frequent financing, and can compress project timelines or force prioritization away from less mature programs if funding costs or access tighten.
Negative Stockholders' Equity Weakens Financial FlexibilityNegative shareholders' equity reflects accumulated deficits exceeding capital, which can limit borrowing capacity and raise creditor and investor concern. Over the medium term, this condition increases dependency on dilutive equity raises and may raise the cost of capital needed to advance clinical programs.
Faeth Therapeutics News
4070 FAQ
What was Faeth Therapeutics’s price range in the past 12 months?
Faeth Therapeutics lowest stock price was €5.70 and its highest was €6.00 in the past 12 months.
What is Faeth Therapeutics’s market cap?
Faeth Therapeutics’s market cap is €641.07M.
When is Faeth Therapeutics’s upcoming earnings report date?
Faeth Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 15 days.
How were Faeth Therapeutics’s earnings last quarter?
Faeth Therapeutics released its earnings results on May 15, 2026. The company reported -€115.453 earnings per share for the quarter, missing the consensus estimate of -€0.545 by -€114.908.
Is Faeth Therapeutics overvalued?
According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued.
Does Faeth Therapeutics pay dividends?
Faeth Therapeutics does not currently pay dividends.
What is Faeth Therapeutics’s EPS estimate?
Faeth Therapeutics’s EPS estimate is -2.85.
How many shares outstanding does Faeth Therapeutics have?
Faeth Therapeutics has 25,778,753 shares outstanding.
What happened to Faeth Therapeutics’s price movement after its last earnings report?
Faeth Therapeutics reported an EPS of -€115.453 in its last earnings report, missing expectations of -€0.545. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Faeth Therapeutics?
Currently, no hedge funds are holding shares in DE:4070
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faeth Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€48.01 (700.23% Upside)
€48.01 (700.23% Upside)
Insider Transactions
Bought Shares
Worth €725.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
436.62%
Trailing 12-Months
Company Description
Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
4070 Stock 12 Month Forecast
Average Price Target
€48.01
▲(700.23% Upside)
Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―